The DOI matches its Crossref record; 230 of the 230 references it cites were found in a registry or an index.
Nicotine receptor partial agonists for smoking cessation
Open accessAbstract
Nicotine receptor partial agonists for smoking cessation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The use of effective drugs to treat nicotine-dependence (e.g., nicotine patches, nicotine gum, and varenicline)356, 357) combined with counseling for psychological dependence increase the success rate of smoking cessation.”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [356]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Nicotine replacement therapy for smoking cessation
Stead, L. F., Perera, R., Bullen, C., Mant, D., Hartmann‐Boyce, J., Cahill, K., & Lancaster, T. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000146.pub4 · Cited by 2,564
Self-citationAntidepressants for smoking cessation
Howes, S., Hartmann-Boyce, J., Livingstone-Banks, J., Hong, B., & Lindson, N. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000031.pub5 · Cited by 1,352
Outcome criteria in smoking cessation trials: proposal for a common standard
West, R., Hajek, P., Stead, L., & Stapleton, J. (2005) · Addiction · doi:10.1111/j.1360-0443.2004.00995.x · Cited by 1,285
Pharmacological interventions for smoking cessation: an overview and network meta-analysis
Cahill, K., Stevens, S., Perera, R., & Lancaster, T. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009329.pub2 · Cited by 1,243
Self-citationAnthenelli, R. M., Benowitz, N. L., West, R., St Aubin, L., McRae, T., Lawrence, D., Ascher, J., Russ, C., Krishen, A., & Evins, A. E. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30272-0 · Cited by 1,177
Measures of abstinence in clinical trials: issues and recommendations
Hughes, J. R., Keely, J. P., NIAURA, R. S., Ossip-Klein, D. J., RICHMOND, R. L., & Swan, G. E. (2003) · Nicotine & Tobacco Research · doi:10.1093/ntr/5.1.13 · Cited by 1,058
Varenicline: An α4β2 Nicotinic Receptor Partial Agonist for Smoking Cessation
Coe, J. W., Brooks, P. R., Vetelino, M. G., Wirtz, M. C., Arnold, E. P., Huang, J., Sands, S. B., Davis, T. I., Lebel, L. A., Fox, C. B., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050069n · Cited by 930
Research works printed but not linked: 38
- Aubin, 2008, Authors' reply [to JE Rose], Thorax, 63, 752
- Aubin, 2008, Authors' reply [to T Hillman], Thorax, 63, 752
- Brinn, 2013, Cost effectiveness of an inpatient smoking cessation intervention for patients with tobacco related illnesses (Stop Trial): a multi-centre RCT [Abstract], Respirology (Carlton, Vic.), 18, 16 [O027]
- Carson, 2015, Superiority of a course of varenicline tartrate plus counselling over counselling alone for smoking cessation: a 24-month randomized controlled trial for inpatients, Respirology, 20, 115
- Carson, 2010, Varenicline tartrate and counselling versus counselling alone in a randomised controlled trial for inpatient smoking cessation: 3 month interim results [Abstract], Respirology, 15, A30
- Hnin, 2014, Triggers resulting in relapse: cohort analysis from the smoking termination opportunity for inpatients (STOP) trial [Abstract], Respirology (Carlton, Vic.), 19, 40 [TO 076]
- Anthenelli R Benowitz N West R St Aubin L McRae T Lawrence D Reports of suicidal ideation and behavior in the EAGLES trial Proceedings of the Society for Research on Nicotine and Tobacco, USA 3rd - 5th March 2016 8
- Benowitz N Evins AE West R St Aubin L McRae T Lawrence D EAGLES trial: study design and neuropsychiatric safety results Proceedings of the Society for Research on Nicotine and Tobacco, USA 3rd - 5th March 2016 7
- Prochaska J Neuropsychiatric risk concerns in the context of smoking, quitting, and cessation pharmacotherapy use Proceedings of the Society for Research on Nicotine and Tobacco, USA 3rd - 5th March 2016 7
- Prochaska J Benowitz N West R Anthenelli R Evaluating adverse events in a global smoking cessation study (EAGLES): a randomized controlled tiral comparing the safety and efficacy of the first-line smoking cessation aids in smokers with and without pychiatric disorders Proceedings of the Society for Research on Nicotine and Tobacco, USA 3rd - 5th March 2016 7
- West R Benowitz N Evins AE St Aubin L McRae T Lawrence D Relative efficacy of varenicline, bupropion SR, and nicotine transdermal patch in aiding smoking cessation in the EAGLES trial Proceedings of the Society for Research on Nicotine and Tobacco, USA 3rd - 5th March 2016 8
- Bastian H Comment on Ebbert 2015 'Reduce to Quit' trial www.ncbi.nlm.nih.gov/pubmed/?term=25688780
- Evins, 2013, Extended duration pharmacotherapy with varenicline prevents relapse to smoking in adult smokers with schizophrenia, Neuropsychopharmacology, 38, S63
- Meszaros, 2012, Varenicline treatment of alcohol and nicotine dependence in schizophrenia: Problems encountered in a pilot trial, American Journal on Addictions / American Academy of Psychiatrists in Alcoholism and Addictions, 21, 393
- Nakamura, 2007, Efficacy and tolerability of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokers, Clinical Therapeutics, 29, 1040, 10.1016/j.clinthera.2007.06.012 · DOI
- Rigotti, 2010, A randomized trial of varenicline for smoking cessation in patients with cardiovascular disease: analysis of efficacy by baseline characteristics, Circulation, Conference, 2
- Benndorf, 1970, Smoking cessation treatment with cytisin (Tabex®): half-yearly outcomes for former smokers abstinent at four weeks from beginning of treatment, Das Deutsche Gesundheitwesen, 24, 774
- Benndorf, 1969, Further reports on a double blind trial of the Bulgarian cytisine compound Tabex® on 1214 smokers wishing to quit and practical experience in conducting clinics for such smokers, Das Deutsche Gesundheitswesen, 24, 1135
- Benndorf, 1968, Results of smoking cessation treatment with cytisin (Tabex®), Das Deutsche Gesundheitwesen, 23, 2092
- Scharfenberg, 1971, Cytisine (Tabex®) as a treatment for smoking cessation, Das Deutsche Gesundheitwesen, 26, 463
- O'Brien, 2007, Varenicline as maintenance therapy, Current Psychiatry Reports, 9, 348
- Fagerström, 2010, Varenicline treatment for smoking cessation in Asian populations: a pooled analysis of placebo-controlled trials conducted in six Asian countries, Current medical Research & Opinion, 26, 2165, 10.1185/03007995.2010.505130 · DOI
- Fagerström, 2010, Varenicline treatment for smoking cessation in Asian populations: a pooled analysis of placebo-controlled trials conducted in six Asian countries, Current medical Research & Opinion, 26, 2165, 10.1185/03007995.2010.505130 · DOI
- Westergaard, 2014, The effect of varenicline on smoking cessation in a group of young asthma patients, American Journal of Respiratory and Critical Care Medicine, 189, A1091
- Reeves K Watsky E Williams K Azoulay S Billing B Gong J The safety of varenicline taken for 52 weeks for smoking cessation [RPOS3-54] Society for Research on Nicotine and Tobacco 12th Annual Conference Orlando Fla, USA 2006
- Falk, 2014, A double-blind, placebo-controlled trial assessing the efficacy of varenicline tartrate for alcohol dependence, Alcoholism, Clinical and Experimental Research, 38, 139A
- Granatowicz, 1976, Smoking cessation through the use of cytisine and other therapy, World Smoking Health, 1, 8
- Hartwell, 2014, Pharmacogenetics of naltrexone and varenicline in heavy drinking smokers, Alcoholism, Clinical and Experimental Research, 38, 223A
- Bacvarov, 1967, Smoking cessation through medication: remarks on G. Scharfenberg, E Winkelvoss and S. Benndorf, Munch Med Wschr. 109 (1967) 1687-1689, Munchener Medizinische Wochenschrift, 109, 2663
- Kempe, 1967, Observation about the Bulgarian medicine for smoking withdrawal Tabex, produced by Pharmachim-Sofia, Savr Med, 18, 355
- Paun, 1968, [Smoking cessation with cytisine 'Tabex' tablets] [German], Sonderduck aus das deutsche Gesundheitwesen, 23, 2088
- Paun, 1970, Tabex: registering and treatment of smokers with chronic bronchitis in the consultation against tobacco smoking - Berlin, Medico-Biologic Information, 3, 15
- Shim, 2011, Varenicline treatment for smoking cessation in people with schizophrenia: a randomized double-blind placebo-controlled trial, Schizophrenia Bulletin, 37, 320
- Stoyanov, 1972, [On the therapeutic effectiveness and tolerability of Tabex] [Bulgarian], Savremenna Medicina, 23, 30
- Wiratmoko, 2013, Efficacy of varenicline, an nicotinic acetylcholine receptor partial agonist, vs placebo for smoking cessation. A randomized controlled trial, Respirology (Carlton, Vic.), 18, 66 [OS205]
- Reid, 2010, Varenicline versus transdermal nicotine patch for smoking cessation in patients with coronary heart disease: A pilot randomized trial, Canadian Journal of Cardiology, 26, 53D
- Smith, 2013, Varenicline effects on smoking, cognition, and psychiatric symptoms in schizophrenia, Neuropsychopharmacology, 38, S364
- Tutka, 2006, Cytisine - renaissance of well known alkaloid. Pharmacological aspects of efficacy in the treatment of tobacco dependence [Polish], Farmakoterapia w Psychiatrii i Neurologii, 1, 33
Cited by
Sorted by citations
Items 401–432 of 432
Citisiniclina no Tratamento Farmacológico da Cessação Tabágica: Uma Revisão Baseada na Evidência
Vicente, A. F., & Lourenço, O. B. (2022) · Gazeta Médica · doi:10.29315/gm.v1i1.592
Bernat, P., Kołodziejczyk, P., Łuszczki, J. J., Zagaja, M. P., & Tutka, P. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032616
Comparative effect of varenicline and nicotine patches on preventing repeat cardiovascular events
Robijn, A. L., Filion, K. B., Woodward, M., Hsu, B., Chow, C. K., Pearson, S., Jorm, L. R., Falster, M. O., & Havard, A. (2023) · Heart · doi:10.1136/heartjnl-2022-322170
Caponnetto, P., Maglia, M. G., Casu, M., Prezzavento, G. C., Campagna, D., Petralia, A., Polosa, R., & CoEHAR Study Group (2023) · doi:10.2196/preprints.47993
Mycotherapeutics Affecting Dopaminergic Neurotransmission to Exert Neuroprotection
Kim, S., Nadar, R. M., DeRuiter, J., Pathak, S., Ramesh, S., Moore, T., Agrawal, D. C., & Dhanasekaran, M. (2023) · Springer eBooks · doi:10.1007/978-981-19-9550-7_13
Wirtz, M. R., Stanton, A. M., Manohar, R. R., Labbe, A. K., Zvolensky, M. J., Smits, J. A. J., Hoeppner, B. B., & O’Cleirigh, C. M. (2023) · Journal of Studies on Alcohol and Drugs · doi:10.15288/jsad.22-00318
Evidence of the Impact of Smoking Cessation
Cavaco‐Silva, P., & Pintado, S. (2023) · Springer eBooks · doi:10.1007/978-3-030-50247-8_17-1
Evidence of the Impact of Smoking Cessation
Cavaco‐Silva, P., & Pintado, S. (2023) · Springer eBooks · doi:10.1007/978-3-030-64477-2_17
Recommandations pour des soins préventifs pour promouvoir l’équité en matière de santé
Persaud, N., Sabir, A., Woods, H., Sayani, A., Agarwal, A., Chowdhury, M., de Leon-Demare, K., Ibezi, S., Jan, S. H., Katz, A., et al. (2023) · Canadian Medical Association Journal · doi:10.1503/cmaj.230237-f · Cited by 1
Therapie der Tabakabhängigkeit
Jähne, A., Mühlig, S., Rüther, T., & Batra, A. (2023) · Zahnmedizin up2date · doi:10.1055/a-2200-0281
Laurenz, L. J., & Thomasius, R. (2023) · Springer eBooks · doi:10.1007/978-3-662-65267-1_25
Traitements du sevrage tabagique
Verdier, C., & Aubin, H. (2023) · Elsevier eBooks · doi:10.1016/b978-2-294-77934-3.00072-x
Vanderkam, P., Pomes, C., Dzeraviashka, P., Castéra, P., Jaafari, N., & Lafay‐Chebassier, C. (2024) · CNS Spectrums · doi:10.1017/s1092852924000087
Smoking and determination of workworthiness in industrial enterprises of the highlands
Strizhakov, L. A., Brimkulov, N. N., & Babanov, S. A. (2024) · Russian Journal of Occupational Health and Industrial Ecology · doi:10.31089/1026-9428-2024-64-3-189-192
Hameed, A. A. (2024) · International Journal of Science and Research (IJSR) · doi:10.21275/sr24801160047 · Cited by 1
Kock, L. S., Brown, J., Boelen, L., West, R., Shardlow, N., & Shahab, L. (2024) · Wellcome Open Research · doi:10.12688/wellcomeopenres.22813.1
Current Treatments for Substance Use Disorders
D’Sa, A., Gaddis, A., & Strain, E. C. (2025) · Oxford University Press eBooks · doi:10.1093/med/9780197640654.003.0050
Grundlagen der Diagnostik und Therapie
(2024) · Elsevier eBooks · doi:10.1016/b978-3-437-22487-4.16001-0
Addictions and Substance Misuse
(2025) · Wiley eBooks · doi:10.1002/9781119870203.mpg004.pub2
Mastrostefano, A., Greco, G., Bacco, C. D., Davini, F., Polito, G., Carnevale, E., Anastasi, G., & Terracina, S. A. (2025) · Targets · doi:10.3390/targets3030024
REACT to NHST: Sensible conclusions for meaningful hypotheses
Izbicki, R., Cabezas, L. M. C., Colugnati, F. A. B., Lassance, R. F. L., de Souza, A. A. L., & Stern, R. B. (2025) · The Quantitative Methods for Psychology · doi:10.20982/tqmp.21.2.p043 · Cited by 1
Recommandations sur les interventions de cessation tabagique pour les adultes au Canada
Thombs, B. D., Traversy, G., Reynolds, D. L., Lang, E., Groulx, S., & Wilson, B. J. (2025) · Canadian Medical Association Journal · doi:10.1503/cmaj.241584-f
Eight ways to quit smoking in 2021 – what the science says
Hartmann‐Boyce, J., & Lindson, N. (2021) · doi:10.64628/ab.xggkmvkc7
Sinha, A., Wasnik, M., & Chevvuri, R. (2025) · Indian Journal of Community Medicine · doi:10.4103/ijcm.ijcm_790_24
Akman, C., Akgün, F. S., Özel, B. A., Özkaya, B., Afacan, G., & Karcıoğlu, Ö. (2026) · Current Pharmaceutical Design · doi:10.2174/0113816128418550251030044713
Baldwin, A. N., & Banks, M. L. (2026) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2026.113131
Approche thérapeutique et cognitive chez les patients souffrant d'une addiction au tabac
Vanderkam, P. (2023) · theses.fr (ABES) · doi:10.70675/307f9e53z9985z46a6z8c9dz1701c02f2849
Li, X., Zeng, L.-L., Jiang, X.-Q., Yao, J., Song, L.-J., Xu, J.-H., Teng, J.-F., Liu, S., Wu, B., & Hu, K.-H. (2026) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5c00860
An Update for Varenicline (Chantix) in 2026: Still Effective and Still Safe
Mills, J. (2026) · Issues in Mental Health Nursing · doi:10.1080/01612840.2026.2679935
Natural History and Nonoperative Treatment of Intermittent Claudication
Ulloa, J. G. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-28432-8.00034-x
Metadata
- Authors
- Cahill, K., Lindson-Hawley, N., Thomas, K. H., Fanshawe, T. R., & Lancaster, T.
- Affiliations
- University of Oxford (GB)
- University of Oxford; Nuffield Department of Primary Care Health Sciences; Radcliffe Observatory Quarter Woodstock Road Oxford UK OX2 6GG
- University of Bristol (GB)
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2016-05-09
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W4294253676
- Cited by
- 433
- References
- 230
- Citations by year
- 2026: 5 · 2025: 22 · 2024: 32 · 2023: 57 · 2022: 55 · 2021: 65 · 2020: 34 · 2019: 52 · 2018: 49 · 2017: 43 · 2016: 8
- FWCI
- 6.00
- Type
- journal article
- Language
- en
- Update notices
- new_version (2023-05-05)
- Open access
- bronze
- doi.org
- Locations
- Cochrane Database of Systematic Reviews (publishedVersion)
- Bristol Research (University of Bristol) (publishedVersion, other-oa)
- Research Portal (King's College London) (submittedVersion)
- Explore Bristol Research (submittedVersion, other-oa)
- Funders
- National Institute for Health and Care Research (15/58/18, HTA/15/58/18, CL-2013-25-003)
- Academy of Medical Sciences (AMS-SGCL12-Thomas)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Smoking Behavior and Cessation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nicotinic Acetylcholine Receptors Study
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Keywords
- nicotine receptor partial agonist, smoking cessation, nicotine replacement therapy, varenicline, bupropion, nicotine dependence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
